|
N4BP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.13690000536471E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.43099999966512E-07 |
| Normal-vs-Stage2 |
3.197800E-04 |
| Normal-vs-Stage3 |
1.56162999999099E-05 |
| Normal-vs-Stage4 |
4.19849999988564E-07 |
| Stage1-vs-Stage2 |
8.999200E-01 |
| Stage1-vs-Stage3 |
6.384800E-01 |
| Stage1-vs-Stage4 |
1.896970E-01 |
| Stage2-vs-Stage3 |
6.855800E-01 |
| Stage2-vs-Stage4 |
2.511400E-01 |
| Stage3-vs-Stage4 |
3.878200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.84359999997075E-07 |
| Normal-vs-AfricanAmerican |
1.174390E-02 |
| Normal-vs-Asian |
5.013700E-04 |
| Caucasian-vs-AfricanAmerican |
4.890200E-01 |
| Caucasian-vs-Asian |
5.654600E-01 |
| AfricanAmerican-vs-Asian |
7.932800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.60830000001711E-07 |
| Normal-vs-Female |
1.47419999985132E-07 |
| Male-vs-Female |
8.391200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.55270000004693E-06 |
| Normal-vs-Age(41-60Yrs) |
4.11010000000989E-06 |
| Normal-vs-Age(61-80Yrs) |
1.40400000514518E-08 |
| Normal-vs-Age(81-100Yrs) |
1.281980E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.750800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.027900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.123400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.880000E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.197000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.585000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.235190E-01 |
| Classical-VS-Follicular |
1.36949999995917E-06 |
| Classical-VS-Other |
6.068000E-02 |
| Classical-VS-Normal |
5.50639999999936E-05 |
| Tall-VS-Follicular |
1.881970E-01 |
| Tall-VS-Other |
3.311400E-01 |
| Tall-VS-Normal |
2.565200E-04 |
| Follicular-VS-Other |
8.036000E-01 |
| Follicular-VS-Normal |
8.73280003865773E-10 |
| Other-VS-Normal |
2.044600E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.71509999979946E-07 |
| Normal-vs-N1 |
8.37339999559816E-08 |
| N0-vs-N1 |
2.131200E-01 |
|
|
